targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000041880 | EFO_0000616 | NCT03057145 | Completed | 1 | 2017-03-10 | null | null | null | null | null | 1,632,087,572,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03057145 | Completed | 1 | 2017-03-10 | null | null | null | null | null | 1,632,087,572,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03057145 | Completed | 1 | 2017-03-10 | null | null | null | null | null | 1,632,087,572,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03057145 | Completed | 1 | 2017-03-10 | null | null | null | null | null | 1,632,087,572,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03057145 | Completed | 1 | 2017-03-10 | null | null | null | null | null | 1,632,087,572,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03057145 | Completed | 1 | 2017-03-10 | null | null | null | null | null | 1,632,087,572,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02986100 | Completed | 1 | 2016-11-01 | null | null | null | null | null | 1,666,447,312,036 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02986100 | Completed | 1 | 2016-11-01 | null | null | null | null | null | 1,666,447,312,036 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02986100 | Completed | 1 | 2016-11-01 | null | null | null | null | null | 1,666,447,312,036 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02986100 | Completed | 1 | 2016-11-01 | null | null | null | null | null | 1,666,447,312,036 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02986100 | Completed | 1 | 2016-11-01 | null | null | null | null | null | 1,666,447,312,036 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02986100 | Completed | 1 | 2016-11-01 | null | null | null | null | null | 1,666,447,312,036 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02986100 | Completed | 1 | 2016-11-01 | null | null | null | null | null | 1,666,447,312,036 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02986100 | Completed | 1 | 2016-11-01 | null | null | null | null | null | 1,666,447,312,036 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02986100 | Completed | 1 | 2016-11-01 | null | null | null | null | null | 1,666,447,312,036 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02430311 | Completed | 1 | 2015-06-10 | null | null | null | null | null | 1,683,627,181,577 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02430311 | Completed | 1 | 2015-06-10 | null | null | null | null | null | 1,683,627,181,577 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02430311 | Completed | 1 | 2015-06-10 | null | null | null | null | null | 1,683,627,181,577 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02430311 | Completed | 1 | 2015-06-10 | null | null | null | null | null | 1,683,627,181,577 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02430311 | Completed | 1 | 2015-06-10 | null | null | null | null | null | 1,683,627,181,577 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02430311 | Completed | 1 | 2015-06-10 | null | null | null | null | null | 1,683,627,181,577 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02430311 | Completed | 1 | 2015-06-10 | null | null | null | null | null | 1,683,627,181,577 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02430311 | Completed | 1 | 2015-06-10 | null | null | null | null | null | 1,683,627,181,577 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02430311 | Completed | 1 | 2015-06-10 | null | null | null | null | null | 1,683,627,181,577 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01104558 | Completed | 4 | 2008-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 206,158,431,447 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01104558 | Completed | 4 | 2008-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 206,158,431,447 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01104558 | Completed | 4 | 2008-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 206,158,431,447 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01104558 | Completed | 4 | 2008-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 206,158,431,447 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01104558 | Completed | 4 | 2008-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 206,158,431,447 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01104558 | Completed | 4 | 2008-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 206,158,431,447 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00589303 | Terminated | 3 | 2007-12-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 438,086,664,669 | Lack of funding | Phase 3 | 31/12/2007 | Terminated | 04/04/2013 | 31/07/2011 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00589303 | Terminated | 3 | 2007-12-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 438,086,664,669 | Lack of funding | Phase 3 | 31/12/2007 | Terminated | 04/04/2013 | 31/07/2011 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00589303 | Terminated | 3 | 2007-12-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 438,086,664,669 | Lack of funding | Phase 3 | 31/12/2007 | Terminated | 04/04/2013 | 31/07/2011 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00589303 | Terminated | 3 | 2007-12-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 438,086,664,669 | Lack of funding | Phase 3 | 31/12/2007 | Terminated | 04/04/2013 | 31/07/2011 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00589303 | Terminated | 3 | 2007-12-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 438,086,664,669 | Lack of funding | Phase 3 | 31/12/2007 | Terminated | 04/04/2013 | 31/07/2011 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00589303 | Terminated | 3 | 2007-12-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 438,086,664,669 | Lack of funding | Phase 3 | 31/12/2007 | Terminated | 04/04/2013 | 31/07/2011 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02717507 | Active, not recruiting | 2 | 2016-04-04 | null | null | null | null | Phase II+ | 755,914,245,639 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02717507 | Active, not recruiting | 2 | 2016-04-04 | null | null | null | null | Phase II+ | 755,914,245,639 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02717507 | Active, not recruiting | 2 | 2016-04-04 | null | null | null | null | Phase II+ | 755,914,245,639 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02717507 | Active, not recruiting | 2 | 2016-04-04 | null | null | null | null | Phase II+ | 755,914,245,639 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02717507 | Active, not recruiting | 2 | 2016-04-04 | null | null | null | null | Phase II+ | 755,914,245,639 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02717507 | Active, not recruiting | 2 | 2016-04-04 | null | null | null | null | Phase II+ | 755,914,245,639 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,408,749,273,126 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,408,749,273,126 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,408,749,273,126 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,408,749,273,126 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,408,749,273,126 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,408,749,273,126 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00402376 | Terminated | 4 | 2007-04-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,111 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00402376 | Terminated | 4 | 2007-04-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,111 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00402376 | Terminated | 4 | 2007-04-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,111 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00402376 | Terminated | 4 | 2007-04-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,111 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00402376 | Terminated | 4 | 2007-04-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,111 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00402376 | Terminated | 4 | 2007-04-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,111 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00937092 | Unknown status | 4 | 2009-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00937092 | Unknown status | 4 | 2009-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00937092 | Unknown status | 4 | 2009-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00937092 | Unknown status | 4 | 2009-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00937092 | Unknown status | 4 | 2009-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00937092 | Unknown status | 4 | 2009-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,460,288,881,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03421860 | Completed | 4 | 2017-02-23 | null | null | Phase IV | Phase III+ | Phase II+ | 197,568,495,664 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03421860 | Completed | 4 | 2017-02-23 | null | null | Phase IV | Phase III+ | Phase II+ | 197,568,495,664 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03421860 | Completed | 4 | 2017-02-23 | null | null | Phase IV | Phase III+ | Phase II+ | 197,568,495,664 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03421860 | Completed | 4 | 2017-02-23 | null | null | Phase IV | Phase III+ | Phase II+ | 197,568,495,664 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03421860 | Completed | 4 | 2017-02-23 | null | null | Phase IV | Phase III+ | Phase II+ | 197,568,495,664 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03421860 | Completed | 4 | 2017-02-23 | null | null | Phase IV | Phase III+ | Phase II+ | 197,568,495,664 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01178528 | Completed | 3 | 2009-09-01 | null | null | null | Phase III+ | Phase II+ | 214,748,366,854 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01178528 | Completed | 3 | 2009-09-01 | null | null | null | Phase III+ | Phase II+ | 214,748,366,854 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01178528 | Completed | 3 | 2009-09-01 | null | null | null | Phase III+ | Phase II+ | 214,748,366,854 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01178528 | Completed | 3 | 2009-09-01 | null | null | null | Phase III+ | Phase II+ | 214,748,366,854 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01178528 | Completed | 3 | 2009-09-01 | null | null | null | Phase III+ | Phase II+ | 214,748,366,854 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01178528 | Completed | 3 | 2009-09-01 | null | null | null | Phase III+ | Phase II+ | 214,748,366,854 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01042873 | Unknown status | 4 | 2010-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 257,698,038,465 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01042873 | Unknown status | 4 | 2010-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 257,698,038,465 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01042873 | Unknown status | 4 | 2010-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 257,698,038,465 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01042873 | Unknown status | 4 | 2010-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 257,698,038,465 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01042873 | Unknown status | 4 | 2010-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 257,698,038,465 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01042873 | Unknown status | 4 | 2010-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 257,698,038,465 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01868880 | Withdrawn | 4 | 2016-02-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 257,698,038,658 | difficulties in recruiting patients | Phase 4 | 29/02/2016 | Withdrawn | 13/03/2020 | 31/12/2023 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01868880 | Withdrawn | 4 | 2016-02-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 257,698,038,658 | difficulties in recruiting patients | Phase 4 | 29/02/2016 | Withdrawn | 13/03/2020 | 31/12/2023 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01868880 | Withdrawn | 4 | 2016-02-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 257,698,038,658 | difficulties in recruiting patients | Phase 4 | 29/02/2016 | Withdrawn | 13/03/2020 | 31/12/2023 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01868880 | Withdrawn | 4 | 2016-02-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 257,698,038,658 | difficulties in recruiting patients | Phase 4 | 29/02/2016 | Withdrawn | 13/03/2020 | 31/12/2023 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01868880 | Withdrawn | 4 | 2016-02-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 257,698,038,658 | difficulties in recruiting patients | Phase 4 | 29/02/2016 | Withdrawn | 13/03/2020 | 31/12/2023 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01868880 | Withdrawn | 4 | 2016-02-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 257,698,038,658 | difficulties in recruiting patients | Phase 4 | 29/02/2016 | Withdrawn | 13/03/2020 | 31/12/2023 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01060293 | Terminated | 4 | 2009-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 283,467,843,639 | Safety issues in the LDFD-group (higher heart rate with dopamine) | Phase 4 | 31/07/2009 | Terminated | 11/09/2013 | 31/12/2013 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01060293 | Terminated | 4 | 2009-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 283,467,843,639 | Safety issues in the LDFD-group (higher heart rate with dopamine) | Phase 4 | 31/07/2009 | Terminated | 11/09/2013 | 31/12/2013 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01060293 | Terminated | 4 | 2009-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 283,467,843,639 | Safety issues in the LDFD-group (higher heart rate with dopamine) | Phase 4 | 31/07/2009 | Terminated | 11/09/2013 | 31/12/2013 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01060293 | Terminated | 4 | 2009-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 283,467,843,639 | Safety issues in the LDFD-group (higher heart rate with dopamine) | Phase 4 | 31/07/2009 | Terminated | 11/09/2013 | 31/12/2013 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01060293 | Terminated | 4 | 2009-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 283,467,843,639 | Safety issues in the LDFD-group (higher heart rate with dopamine) | Phase 4 | 31/07/2009 | Terminated | 11/09/2013 | 31/12/2013 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01060293 | Terminated | 4 | 2009-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 283,467,843,639 | Safety issues in the LDFD-group (higher heart rate with dopamine) | Phase 4 | 31/07/2009 | Terminated | 11/09/2013 | 31/12/2013 | Safety_Sideeffects | Safety_Sideeffects | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01140399 | Terminated | 4 | 2011-02-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 317,827,580,474 | insufficient enrollment | Phase 4 | 28/02/2011 | Terminated | 10/04/2017 | 30/04/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01140399 | Terminated | 4 | 2011-02-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 317,827,580,474 | insufficient enrollment | Phase 4 | 28/02/2011 | Terminated | 10/04/2017 | 30/04/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01140399 | Terminated | 4 | 2011-02-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 317,827,580,474 | insufficient enrollment | Phase 4 | 28/02/2011 | Terminated | 10/04/2017 | 30/04/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01140399 | Terminated | 4 | 2011-02-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 317,827,580,474 | insufficient enrollment | Phase 4 | 28/02/2011 | Terminated | 10/04/2017 | 30/04/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01140399 | Terminated | 4 | 2011-02-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 317,827,580,474 | insufficient enrollment | Phase 4 | 28/02/2011 | Terminated | 10/04/2017 | 30/04/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01140399 | Terminated | 4 | 2011-02-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 317,827,580,474 | insufficient enrollment | Phase 4 | 28/02/2011 | Terminated | 10/04/2017 | 30/04/2017 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00953303 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 335,007,450,137 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00953303 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 335,007,450,137 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00953303 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 335,007,450,137 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00953303 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 335,007,450,137 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |